Therefore, SIRT6 agonists may be highly synergistic with the above drugs, allowing for lower drug dosages, thereby reducing adverse effects, such as dyslipidemia and itchiness from FXR agonists, carcinogenic risks from FGF19 analogs, and myalgia as well as rhabdomyolysis from PPARα agonists[37]. Here, NR1H4 is linked to metabolic syndrome.